Liquid Biopsy for Precision Oncology Summit West Coast leaderboard
  • Friday, November 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

SmartLab Exchange Europe 2027 Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 26

Novo Nordisk Sues Lilly Over Obesity Drug Advertising Claims

Jul 22, 2026
Novo Nordisk has filed a lawsuit against Eli Lilly and Company and Lilly USA in the United States, alleging that the pharmaceutical giant's advertising for its blockbuster diabetes and…
Read More...

EU Approves Crysvita for Infants With Rare Bone Disease

Jul 22, 2026
The European Commission has approved an expanded indication for Crysvita (burosumab), allowing the therapy to be used in infants aged one month to one year with X-linked…
Read More...

Organon Expands Australia Biosimilar Partnership With Samsung Bioepis

Jul 17, 2026
Organon and Samsung Bioepis have expanded their long-standing partnership to bring a new biosimilar medicine to patients in Australia, strengthening their efforts to improve access to…
Read More...

Telix Opens Advanced Cancer Radiopharmaceutical Facility in Melbourne

Jul 17, 2026
Telix Pharmaceuticals has officially opened a new multi-million-dollar radiopharmaceutical research, manufacturing and treatment facility in Melbourne, Australia, marking a major step…
Read More...

FDA Approves First Oral PCSK9 Inhibitor for High Cholesterol

Jul 17, 2026
Merck, known as MSD outside the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has approved LIPFENDRA (enlicitide) 20 mg tablets for adults…
Read More...

FDA Grants Full Approval to Fabhalta for IgA Nephropathy

Jul 17, 2026
Novartis has announced that the US Food and Drug Administration (FDA) has granted traditional approval to Fabhalta (iptacopan) for adults with primary immunoglobulin A nephropathy…
Read More...

EU Approves Wegovy Pill for Obesity Treatment

Jul 17, 2026
Novo Nordisk has announced that the European Commission (EC) has approved Wegovy® pill (oral semaglutide 25 mg) for the treatment of adults living with obesity or overweight with at…
Read More...

NICE Backs Finerenone for Heart Failure Patients in England

Jul 17, 2026
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending finerenone for adults with heart failure with preserved or mildly reduced…
Read More...

Excalipoint and DP Technology Partner on AI Antibody Discovery Platform

Jul 16, 2026
Excalipoint Therapeutics and DP Technology have announced a strategic collaboration to develop a new artificial intelligence (AI) platform designed to speed up the discovery of T-cell…
Read More...

AdvanCell Raises $315 Million for Cancer Therapy Development

Jul 16, 2026
Clinical-stage radiopharmaceutical company AdvanCell has raised US$315 million in an oversubscribed Series D financing round to accelerate the development of its targeted cancer…
Read More...
Previous 1 … 24 25 26 27 28 … 966 Next
Oligonucleotide-based Therapeutics Summit
LEAP HR: Life Sciences Europe
3rd Annual TRP Target Selection & Drug Design Summit
2nd Structure-Based Drug Design Summit San Diego
Liquid Biopsy for Precision Oncology Summit West Coast
2nd Non-Opioid Pain Therapeutics Summit
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Antigen-Specific Immune Tolerance Summit
7th Operationalize Expanded Access Programs Summit
Viral Vector Process Development & Manufacturing Summit
SmartLab Exchange Europe 2027
8th RNAi-Based Therapeutics Summit
17th World ADC London
PFS & Injectable Drug Devices Europe
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Biomarker Operations & Biospecimen Management
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • OBI Pharma Signs $2 Billion ADC Deal with Novartis
  • Erasca and Bristol Myers Squibb Partner on Pancreatic Cancer Treatment
  • GSK Wins FDA Approval for Nelkarmi in Advanced Lung Cancer
  • OXB Partners with Aura Biosciences for Phase 3 Cancer Drug Development
  • Skylark Bio Advances Hearing Loss Gene Therapy to Younger Children

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Cell Therapy Safety in Autoimmune Disease

7th Operationalize: Expanded Access Programs Summit East…

As AI and ICH M15 Transform Drug Development, Industry…

Industry Leaders Explore the Future of RNA Therapeutics…

Direct RNA Binding Emerges as a Powerful Approach for…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.